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Abstract
The β1-adrenoceptor (β1AR) is a G-protein-coupled receptor (GPCR) that couples1 to the 
heterotrimeric G protein Gs. G-protein-mediated signalling is terminated by phosphorylation of the 
C terminus of the receptor by GPCR kinases (GRKs) and by coupling of β-arrestin 1 (βarr1, also 
known as arrestin 2), which displaces Gs and induces signalling through the MAP kinase 
pathway2. The ability of synthetic agonists to induce signalling preferentially through either G 
proteins or arrestins—known as biased agonism3—is important in drug development, because the 
therapeutic effect may arise from only one signalling cascade, whereas the other pathway may 
mediate undesirable side effects4. To understand the molecular basis for arrestin coupling, here we 
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determined the cryo-electron microscopy structure of the β1AR–βarr1 complex in lipid nanodiscs 
bound to the biased agonist formoterol5, and the crystal structure of formoterol-bound β1AR 
coupled to the G-protein-mimetic nanobody6 Nb80. βarr1 couples to β1AR in a manner distinct to 
that7 of Gs coupling to β2AR—the finger loop of βarr1 occupies a narrower cleft on the 
intracellular surface, and is closer to transmembrane helix H7 of the receptor when compared with 
the C-terminal α5 helix of Gs. The conformation of the finger loop in βarr1 is different from that 
adopted by the finger loop of visual arrestin when it couples to rhodopsin8. β1AR coupled to βarr1 
shows considerable differences in structure compared with β1AR coupled to Nb80, including an 
inward movement of extracellular loop 3 and the cytoplasmic ends of H5 and H6. We observe 
weakened interactions between formoterol and two serine residues in H5 at the orthosteric binding 
site of β1AR, and find that formoterol has a lower affinity for the β1AR–βarr1 complex than for 
the β1AR–Gs complex. The structural differences between these complexes of β1AR provide a 
foundation for the design of small molecules that could bias signalling in the β-adrenoceptors.
Ligand bias in the GPCRs arises through differential activation of the G-protein pathway and 
the arrestin pathway, and has been observed for ligands binding to many different GPCRs 
such as the µ-opioid receptor9, the angiotensin receptor AT1R (ref. 10) and the β-
adrenoceptors β1AR and β2AR (refs. 5,11). The molecular basis for this is poorly understood. 
Biased signalling is a complex process that can arise through several different factors3,12, 
including cellular effects (the concentration and distribution of, for example, G proteins, 
arrestins and GRKs), the kinetics of interaction between the various components, the energy 
landscape of the receptor and its dynamics, and the structure of the ligand–receptor–arrestin 
complex. The relative contributions of each of these factors are unknown and could vary 
between different GPCRs; however, for AT1R there is good evidence from electron 
paramagnetic resonance data that arrestin-biased ligands stabilize a different subset of 
conformations compared with G-protein-biased ligands13. Here we address one aspect of the 
puzzle by determining the structural differences between a formoterol-bound β1AR–βarr1 
complex and a formoterol-bound β1AR–Nb80 complex. Formoterol was chosen because it is 
known to be an arrestin-biased agonist5 and it is also a full agonist for the coupling of Gs to 
β1AR (ref. 14).
The β1AR construct that we used for structure determination of the β1AR–βarr1 complex 
(β83) (Extended Data Fig. 1) contained six mutations to improve thermostability and a C-
terminal sortase sequence to enable the ligation of the phosphorylated peptide V2R6P, which 
is identical to the phosphorylated C-terminal sequence of the vasopressin receptor V2R. To 
test the functionality of this construct, a chimaera between β83 and the V2R C terminus 
(β83–V2R), which enables efficient in vivo phosphorylation of the receptor and arrestin 
recruitment, was constructed. In HEK293 cells, β83–V2R coupled efficiently to the G 
protein Gs and also to βarr2 (β-arrestin 2, also known as arrestin 3), although its coupling 
efficiency was lower compared with that of the control construct β44–V2R, which did not 
contain thermostabilizing mutations (Extended Data Fig. 2). However, β83–V2R maintained 
the arrestin recruitment bias for formoterol with reference to isoprenaline, although the bias 
factor was lower compared with that of β44–V2R (1.45 ± 0.3 and 2.3 ± 0.4, respectively). 
Stimulation of β83–V2R with formoterol also induced the redistribution of βarr1–YFP from 
the cytosol to the plasma membrane and then into endosomes; however, β83–V2R 
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trafficking was apparently slower compared with that of β44–V2R (Extended Data Fig. 2). 
After purification of the β1AR construct β83, the V2R6P peptide was ligated to the C 
terminus of the receptor to give the phosphorylated receptor β1AR6P. βarr1 did not couple 
efficiently to detergent-solubilized β1AR6P, so β1AR6P was inserted into nanodiscs before 
βarr1 coupling (Extended Data Fig. 1). Pharmacological analysis of the β1AR6P–βarr1 
complex in nanodiscs showed that the coupling of βarr1 caused a 36-fold increase in agonist 
affinity compared with the uncoupled β1AR6P, which was lower than the increase observed 
upon the coupling of mini-Gs (2,100-fold) (Extended Data Fig. 1). This implied that β1AR6P 
coupled to arrestin was in an active state—as has been also observed for other GPCRs15—
and that arrestin coupling and G-protein coupling have different effects on the orthosteric 
binding site.
The structure of the formoterol-bound β1AR6P–βarr1 complex in nanodiscs (Fig. 1a–d) was 
determined by cryo-electron microscopy (cryo-EM) (Methods and Extended Data Figs. 3–5) 
in the presence of the antibody fragment Fab30, which locks arrestin into an active 
conformation16. Fab30 is also required to provide sufficient mass for the alignment of the 
particles during structure determination. In the cryo-EM structure, β1AR6P contained six 
thermostabilizing mutations and three additional mutations to improve folding and remove 
palmitoylation (Extended Data Fig. 1). The overall resolution was 3.3 Å, with the best-
resolved regions of the cryo-EM map at the interface between β1AR6P and βarr1, reaching a 
local resolution of 3.2 Å (Extended Data Fig. 3, Extended Data Table 1). We also determined 
the structure of the formoterol-bound β1AR–Nb80 complex in detergent by X-ray 
crystallography at 2.9 Å resolution (Fig. 1e, Extended Data Table 2) to enable a direct 
comparison between β1AR coupled to either βarr1 or Nb80 and bound to the same ligand. 
β1AR in this structure had an N-terminal thioredoxin fusion, four thermostabilizing 
mutations and two additional mutations to improve folding and remove palmitoylation 
(Extended Data Fig. 1). The β1AR–Nb80 complex was too small (approximately 50 kDa of 
ordered protein) for structure determination by single-particle cryo-EM.
The overall structures of formoterol-bound β1AR in the β1AR–Nb80 and β1AR6P–βarr1 
complexes were very similar, with a root-mean-square deviation (r.m.s.d.) of 0.7 Å over 
1,759 atoms. However, there were small but important differences in the extracellular 
surface, intracellular surface and in the orthosteric binding site that explain the differences 
between arrestin coupling and G-protein coupling. β1AR6P in complex with βarr1 was also 
very similar to β2AR coupled to heterotrimeric Gs (Protein Data Bank (PDB) ID: 3SN6; 
r.m.s.d. 1.1 Å over 1,453 atoms)7,17. This enabled a detailed comparison between β1AR6P–
βarr1, β2AR–Gs and β1AR–Nb80. The thermostabilizing mutations used in all the structures 
presented here do not prevent the coupling of G proteins17 or of βarr1 (Extended Data Figs. 
1, 2); however, they could alter the kinetics of interactions, and we also cannot rule out any 
minor effects of the mutations on the structures.
The overall structure of βarr1 coupled to β1AR6P (Fig. 2a) is very similar to the X-ray 
structure of visual arrestin (also known as S-antigen or arrestin 1) coupled to rhodopsin8 
(PDB ID: 5W0P; r.m.s.d. 1.3 Å, 1,853 atoms) and the structure of activated βarr1 coupled to 
Fab30 and the V2Rpp peptide16 (PDB ID: 4JQI; r.m.s.d. 1.1 Å, 1,861 atoms). The buried 
surface area of β1AR6P that makes contact with βarr1 (approximately 1,200 Å2; excluding 
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the phosphopeptide interface involving residues Glu356–Asp368) is slightly smaller than the 
surface area of rhodopsin that makes contact with visual arrestin (around 1,400 Å2). In 
addition, there is a 20° difference in the tilt of arrestin relative to rhodopsin compared with 
that of βarr1 relative to β1AR6P (Extended Data Fig. 6). However, the regions of β1AR6P 
and rhodopsin that make contact with either βarr1 or visual arrestin, respectively, are 
conserved, as are the positions on the arrestin molecules that make contacts to the receptors 
(Extended Data Figs. 7, 8). The position of the C-terminal V2R6P segment in the cryo-EM 
structure of β1AR6P–βarr1 is also almost identical to the position of the peptide in the 
crystal structure of the βarr1–Fab30–V2Rpp complex (Extended Data Fig. 6), with the 
exception of the phosphate on Thr359. Phospho-Thr359 does not make any contacts to βarr1 
in the βarr1–Fab30–V2Rpp complex, but it seems to make contact with the tip of the lariat 
loop (Lys294 and His295) of βarr1 in the β1AR6P–βarr1 complex. No density was observed 
in the β1AR6P–βarr1 cryo-EM structure that is equivalent to the N-terminal region of V2Rpp 
(R[pT]PP[pS] LGP) adjacent to the finger loop in the βarr1–Fab30–V2Rpp structure; this 
would clash with the new orientation of the finger loop and the receptor in the β1AR6P–
βarr1 complex. The most notable difference between these three structures is the orientation 
and structure of the finger-loop region (Fig. 2b–e). In the activated non-receptor-bound 
βarr1–Fab30–V2Rpp structure, the finger loop forms an unstructured region that does not 
superpose either with the finger loop in visual arrestin coupled to rhodopsin or with βarr1 
coupled to β1AR6P. By contrast, the receptor-bound finger loop of visual arrestin and βarr1 
do superpose, but they adopt different structures (Fig. 2c). The finger loop of visual arrestin 
contains a short α-helical region, whereas in βarr1 it forms a β-hairpin. When the arrestin 
molecules are aligned, it also seems that the tip of the β-hairpin of βarr1 protrudes about 5 Å 
deeper into the receptor than does the α-helical region of visual arrestin. A notable 
observation is that the CDR3 loop of nanobody Nb80, which inserts into the receptor, bears 
a strong resemblance to the finger loop of βarr1 (Fig. 2d), although the polypeptides run in 
antiparallel directions and show little sequence similarity except for the Val–Leu residues at 
the tip of the loops. One caveat in the comparison of the finger-loop structures is that βarr1 
coupled to β1AR6P contains a leucine-to-cysteine mutation at residue 68 (L68C) at the base 
of the finger loop, pointing away from the receptor towards the lipid bilayer; we cannot rule 
out that this mutation has an effect on the structure of the finger loop.
After this work was completed, cryo-EM structures of βarr1 in complex with neurotensin 
receptor 1 (NTSR1) in detergent were published18,19. Comparison with the β1AR6P–βarr1 
complex showed two key differences. The finger loop of βarr1 in complex with NTSR1 
contains an α-helix and does not penetrate deeply into the receptor; in addition, the 
orientation of βarr1 with respect to NTSR1 differs from that with respect to β1AR by 
approximately 80° about an axis perpendicular to the membrane plane (Extended Data Fig. 
6), and by a 10° rotation towards the membrane owing to the structures being determined in 
detergent. A cryo-EM structure of the muscarinic M2 receptor–βarr1 complex20 in 
nanodiscs seems to be similar to that of the β1AR6P–βarr1 complex. These structures 
highlight an unexpected diversity in the coupling arrangement of arrestin to GPCRs, 
analogous to the diversity of G-protein coupling21.
There are 116 atomic contacts (3.9 Å or less) between 27 residues in β1AR6P and 20 
residues in βarr1, comprising 107 van der Waals interactions (92%) and 9 hydrogen bonds 
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(excluding interactions to the phosphopeptide). All structural elements on the cytoplasmic 
face of β1AR, with the exception of H1 and intracellular loop (ICL)3, make contacts with 
βarr1 (Extended Data Fig. 7). In βarr1 there are seven structural elements that make contact 
with the receptor—namely the β-sheets S5, S6 and S15 and the loops s5s6 (finger loop), 
s8s9 (middle loop), s15s16 (C-loop) and s17s18 (Extended Data Fig. 8). The nomenclature 
for structural elements and numbering in arrestin is that implemented in GPCRdb22. The 
majority of contacts made by β1AR6P are mediated by ICL2 (45% of total contacts), which 
interacts with S5, s5s6, S15 and s17s18 in βarr1. In βarr1, the finger loop makes the 
majority of contacts with the receptor (37% of total contacts), with the majority of these 
contacts being made to H6, H2 and ICL2. Of the 27 amino acid residues in β1AR at the 
interface, 40% of the contacts are made by residues Phe14734.51, Gln15034.54, Thr1544.38 
and Arg1554.39 (Extended Data Fig. 7; superscripts denote Ballesteros–Weinstein numbering 
for GPCRs23). Residues in βarr1 that make the most contacts are Arg285s17s18.11, 
Leu71s5s6.08 and Tyr249S16.03 (Extended Data Fig. 7).
Acidic phospholipids are known to have an important role in the binding of arrestin to 
GPCRs24,25. Mutagenesis of arrestin26–29 identified six loops that interact with the lipid 
bilayer and residues that bind phosphoinositides30 (Extended Data Fig. 8). In nanodiscs, the 
β1AR6P–βarr1 structure is shown in relation to the surface of the lipid bilayer (Fig. 1b). This 
enabled the identification of 32 amino acid residues in βarr1 that potentially interact with 
lipid head groups. Ordered density for the negatively charged lipids (phosphatidylglycerol) 
was not observed, but the regions identified are consistent with the biochemical data 
(Extended Data Fig. 8). The L68C mutation at the base of the finger loop is also accessible 
to the lipid bilayer, and this is consistent with functional labelling of βarr1 by 
monobromobimane at this position31. Coupling of the G protein Gs is also known to be 
influenced by phosphoinositides32, and it will be of interest to see whether the lipid 
composition of membranes can affect biased signalling in GPCRs.
The structure of the formoterol-bound β1AR6P–βarr1 complex was compared with that of 
the β2AR–Gs complex7. β1AR and β2AR have 59% sequence identity—excluding the N 
terminus, C terminus and ICL3—and have very similar inactive state structures (r.m.s.d. 0.4–
0.6 A)33,34 and active state structures coupled to nanobodies (r.m.s.d. 0.4–0.6 Å)6,17,35. The 
comparison is therefore justified, but we cannot exclude the possibility that Gs couples to 
β1AR in a different manner to its coupling to β2AR. Superposition of β1AR and β2AR from 
the respective complexes (r.m.s.d. 1.0 Å, 1,634 atoms) shows that the long axis of βarr1 is at 
an approximately 90° angle to the long axis of Gs (Extended Data Fig. 6). The most obvious 
difference in structure between the different receptors is that the cytoplasmic end of H6 is an 
additional 7 Å away from the receptor in β2AR–Gs compared with in β1AR6P–βarr. The 
cleft in the intracellular face is thus 8 Å narrower (Fig. 3b, c) when βarr1 is coupled to β1AR 
compared with when Gs is coupled to β2AR (measured between the Cα of Ser3468.47–
Arg2846.29 in β1AR and the Cα of Ser3298.47–Lys2676.29 in β2AR). The amino acid 
residues that form the interface between β1AR6P and βarr1 are very similar to those that 
form the interface between β2AR and Gs (Fig. 3a). In particular, both complexes rely on 
extensive contacts between ICL2 and the cytoplasmic end of H3 of the receptor and either 
βarr1 or Gs. However, there are contacts between the cytoplasmic ends of H2, H3, H7 and 
H8 in the β1AR6P–βarr1 complex that are absent in the β2AR–Gs complex. There are also 
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more extensive contacts between H5 and H6 of β2AR to Gs compared with in the β1AR6P–
βarr1 complex. The amino acid side chains in β1AR and β2AR at the respective interfaces 
are also similarly positioned, with the exception of Arg3.50 (Arg139 in β1AR and Arg131 in 
β2AR) in the DRY motif (Fig. 3d, e). In the β2AR–Gs complex—and also in related 
complexes, such as that between the adenosine A2A receptor and Gs 36—Arg3.50 extends 
away from the helix axis of H3 to form an interface between Tyr391H5.23 of the G protein 
and the hydrophobic interior of the receptor (Fig. 3e). By contrast, Arg3.50 in the β1AR6P–
βarr1 complex adopts a different rotamer that makes extensive polar interactions with 
Asp1383.51 and Thr762.39 in the receptor and with Asp69s5s6.6 of βarr1 in the finger loop 
(Fig. 3d). The rotamer of Arg3.50, and its interactions to other β1AR side chains in the 
β1AR6P–βarr1 complex, are similar to those observed in inactive state structures of β1AR 
and in active state structures stabilized by nanobodies17,34. One final observation in the 
comparison between the β1AR6P–βarr1 and the β2AR–Gs complexes is that the α5 helix of 
Gs does not overlap precisely with the position of the finger loop of βarr1; the finger loop 
lies closer to H7–H8 than does the α5-helix (Fig. 3b, c).
To identify structural changes in β1AR when G protein dissociates and arrestin couples, we 
compared the structures of formoterol-bound β1AR6P–βarr1 and formoterol-bound β1AR–
Nb80 (Nb80 being a known mimetic of the G protein Gs; ref. 6). The largest differences 
were observed on the intracellular face of β1AR, where the ends of H5 and H6 were closer 
to the receptor core by 6.7 Å (Cα of Ile241) and 1.9 Å (Cα of Lys284), respectively, when 
βarr1 was coupled compared with when Nb80 was coupled (Fig. 4b). On the extracellular 
face of the receptor (Fig. 4c), the largest difference is in extracellular loop (ECL)2, which 
occludes the entrance to the orthosteric binding pocket through a 2.2 Å shift in its position 
upon arrestin coupling (as measured at Cα of Arg317ECL3). There was no notable density 
for side chains in ECL3 of the β1AR–βarr1 structure, so we cannot compare changes in their 
interactions. In the orthosteric binding site there were considerable differences in the 
interactions between formoterol and β1AR upon arrestin coupling (Fig. 4a), with an overall 
reduction in atomic contacts of 11%. The largest reduction was with H3 and H5, and there 
was an increase in interactions between formoterol and H6 (Extended Data Fig. 7). 
Structures of β1AR bound to the arrestin-biased ligands carmoterol or carvedilol (Fig. 4d) 
also implicated the extracellular region of H6 in the action of ligand bias34,37. The 50% 
decrease in atomic contacts between formoterol and H5 is particularly notable. This includes 
the loss of two hydrogen bonds to Ser2115.41 (Fig. 4a) and lengthening of the remaining 
hydrogen bond. In addition, the hydrogen bond between Ser2155.46 and formoterol 
lengthens by 0.5 Å, and Ser2155.46 is known to be a key residue in receptor activation6,7,34. 
The data are all consistent with the decreased affinity of formoterol to β1AR6P when βarr1 is 
coupled compared with when mini-Gs is coupled (Extended Data Fig. 1). These observations 
can be combined into a model that describes changes in β1AR in the transition from the G-
protein-coupled state to the arrestin-coupled state (Extended Data Fig. 9). Upon G-protein 
dissociation and arrestin coupling, there is an inward movement of the cytoplasmic end of 
H5, resulting in its outward movement away from the ligand in the orthosteric binding site. 
This results in weakening of interactions between formoterol and H5 and a subtle adjustment 
of the ligand in the orthosteric binding site, resulting in a weakening of interactions with H3 
and additional interactions with H6.
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The structure of β1AR6P–βarr1 suggests the possibility of designing biased agonists that, 
when bound, result in a repositioning of H5 compared with its location in the presence of 
balanced agonists. There are also new opportunities for developing drugs that bind 
specifically to the receptor–arrestin complex, rather than the receptor–G protein complex, 
where they differ on the intracellular surface (Extended Data Fig. 9). The challenge will be 
to design compounds that specifically target these sites.
Methods
Cloning, expression and purification of β1AR
The turkey (Meleagris gallopavo) β1AR construct used for crystallization (Extended Data 
Fig. 1) of the β1AR–Nb80 complex (trx-β1AR) was based on β44-m23 (ref. 34). The 
construction of trx-β1AR has been described previously17. Relative to wild-type β1AR, trx-
β1AR contains truncations at the N and C termini (upstream of A33 and downstream of 
L367, respectively) and in the third intracellular loop (C244 to R271, inclusive). 
Thioredoxin (Escherichia coli trxA, with mutations C32S and C35S) was attached to the N 
terminus via the linker EAAAK. trx-β1AR also contains the four thermostabilizing 
mutations (R68S1.59, M90V2.53, F327A7.37 and F338M7.48) as well as two additional 
mutations C116L3.27 and C358A8.59. A hexahistidine tag is fused to the C terminus of trx-
β1AR.
The turkey β1AR construct used for cryo-EM of the β1AR6P–βarr1–Fab30 complex (β83) 
was also based on β44-m2334. β83 shares the same truncations at the N terminus and in the 
third intracellular loop as trx-β1AR (Extended Data Fig. 1). β83 contains six 
thermostabilizing mutations (M44C1.35, M90V2.53, V103C2.66, D322K7.32, F327A7.37 and 
F338M7.48) as well as three additional mutations C116L3.27, E130W3.41 and C358A8.59. The 
sequence downstream of C358A8.59 has been replaced with a linker sequence mimicking the 
C-terminal tail of vasopressin receptor 2 (V2R). The sequence contains a sortase recognition 
site (in bold) followed by a heptahistidine tag [ARGRPLPETGGGRRHHHHHHH]. The 
sortase site is positioned so as to maintain the relative distance between helix H8 in V2R and 
the conserved phosphoserine triad motif after sortase-mediated assembly (see below). MBP-
β83 is identical to β83 except for an N-terminal maltose-binding protein fusion constructed 
with a flexible linker region.
For generating β1AR Tango assay constructs, the coding region of β44 (β44-m23 without 
thermostabilizing mutations—that is, wild-type β1AR with aforementioned truncations at 
the N- and C termini and ICL3 and the mutations C116L3.27 and C358A8.59) and β83 were 
amplified by PCR and cloned using BamHI and KpnI into an in-house Tango assay vector 
(synthesized by GenScript on pCDNA3.1 backbone) containing the V2R C-terminal 
sequence, a downstream TEV protease cleavage site (ENLYFQL) and tetracycline-controlled 
transcription activator (tTA) sequence. These constructs also contain an N-terminal HA 
signal sequence followed by a Flag tag. For confocal microscopy studies, β44 and β83 
coding regions were sub-cloned into pCDNA3.1 vector containing the N-terminal HA signal 
sequence and Flag tag as well as the V2R C-terminal sequence. All β1AR constructs used in 
the functional assays contain the C-terminal region of V2R. For simplicity, they are simply 
referred to as β44–V2R and β83–V2R (Extended Data Fig. 1), and collectively as β1AR–
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V2R. All constructs were sequence validated (Macrogen). HEK-293 cells were purchased 
from ATCC and cultured in DMEM containing 10% FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin. Cells were maintained under sterile conditions in 10-cm culture dishes 
at 37 °C with 5% CO2 and sub-cultured at 70–80% confluency. For functional in vivo 
assays, 60–70% confluent cells were transfected with β1AR–V2R constructs using 
polyethylenimine (PEI) as transfection agent at 1:3 DNA:PEI ratio. The experiments were 
performed 24–48 h after transfection.
The generation of trx-β1AR baculovirus and its expression and subsequent purification were 
performed as described previously17. It was solubilized and purified in decylmaltoside (DM, 
Generon) and eluted off the alprenolol Sepharose ligand affinity column as described 
previously34,39,40 with 100 µM formoterol. The β83 construct was cloned into the 
baculovirus transfer vector pBacPAK8 (Clontech). Baculovirus expressing β83 was prepared 
using the flashBAC ULTRA system (Oxford Expression Technologies). β83 and MBP-β83 
were expressed in Trichoplusia ni cells (Expressions Systems). Cells were grown in 
suspension in ESF 921 medium (Expressions Systems) to a density of 3 × 106 cells per ml. 
Cultures were supplemented with 5% (v/v) fetal bovine serum before infection with β83 
baculovirus and incubated for 40 h.
β83 was solubilized in 2% (w/v) dodecylmaltoside (DDM, Generon) from the membrane 
fraction and further purified in 0.02% (w/v) DDM by Ni2+-affinity chromatography and 
alprenolol Sepharose ligand affinity chromatography. It was eluted from the alprenolol 
Sepharose column with 100 µM alprenolol. β83 was further polished on a Superdex 200 
Increase column to remove excess alprenolol. β1AR6P was generated by sortase A-mediated 
covalent assembly41 of purified β83 with a synthetic phosphopeptide, V2R6P 
(GGGDE[pS]A[pT][pT]A[pS][pS][pS] LAKDTSS, Tufts University Core Facility). The 
expression plasmid for sortase A(P94S/D160N/D165A/K196T) was a gift from S. 
Eustermann and D. Neuhaus. β83 (1 mg/ml) was incubated overnight on ice with tenfold 
molar excess of V2R6P and His-tagged sortase A at 1:10 (mol/mol) enzyme:receptor ratio, in 
the presence of 5 mM CaCl2. The assembly mixture was pre-adjusted with NaOH to pH 7.5 
before the addition of receptor. Unreacted β83 and enzyme were removed by negative Ni2+-
affinity chromatography. β1AR6P was further polished on a Superdex 200 Increase column.
MBP–β83 was purified as β83, except that it was essential that the receptor did not contain 
any ligand, and therefore the ligand affinity chromatography step was not used.
Gs- and arrestin-coupling activity of β1AR–V2R
Surface expression of β1AR–V2R constructs was measured using a whole cell surface 
ELISA protocol described previously42, and it was similar between constructs. In brief, 24 h 
post-transfection, cells were seeded at 0.2 million cells per well in a 24-well plate, pre-
coated with 0.01% (w/v) poly-D-lysine. Cells were washed once with ice-cold TBS, fixed 
with 4% (w/v) paraformaldehyde on ice for 20 min, and washed three times with TBS. The 
cells were incubated with 1% (w/v) BSA solution to block non-specific binding sites 
followed by incubation with HRP-conjugated anti-Flag M2 antibody (Sigma, A8592) 
prepared at 1:10,000 dilution in 1% (w/v) BSA for 90 min. Subsequently, cells were washed 
three times with 1% (w/v) BSA in TBS, 200 µl of TMB substrate was added to cells, and the 
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reaction was stopped using 1 M H2SO4. Absorbance at 450 nm was measured using a multi-
mode plate reader (Victor X4, Perkin Elmer). For normalization, cell density was measured 
using Janus Green staining by incubating the cells with 0.2% (w/v) Janus Green for 20 min 
followed by three washes with 18.2 MΩ cm water and addition of 800 µl of 0.5 M HCl per 
well. The absorbance (A) at 595 nm was read and the A 450:A 595 ratio was used as a 
readout of receptor surface expression.
The Gs-coupling activity of β1AR–V2R was measured using a GloSensor assay as described 
previously43. In brief, HEK-293 cells were co-transfected with β1AR–V2R and the 
luciferase-based cAMP reporter plasmid (pGloSensorTM-22F, Promega). 16–18 h after 
transfection, cells were trypsinized, pelleted and resuspended in buffer (HBSS with 20 mM 
HEPES-NaOH pH 7.4) containing 0.5 mg/ml luciferin (GoldBio). Subsequently, the cells 
were seeded into a white, clear-bottom, 96-well microplate at a density of 0.8–1 × 105 cells 
per 100 µl per well. The plate was kept at 37 °C for 90 min in a CO2 incubator followed by 
30 min at room temperature. The basal reading was first measured in luminescence mode 
using a multi-mode plate-reader (Victor X4, Perkin Elmer). After stimulation with varying 
doses of isoprenaline and formoterol, luminescence was measured continuously over a 
period of 60 min.
Agonist-induced βarr2 recruitment was measured using a Tango assay following a 
previously described protocol44. In brief, HTLA cells were transfected with β1AR–V2R. 24 
h after transfection, cells were trypsinized and seeded at a density of 5 × 104 cells per well in 
a white 96-well microplate. After 16 h, cells were stimulated with varying doses of 
isoprenaline or formoterol for 8 h. Subsequently, culture medium was aspirated and 100 µl 
luciferin (0.5 mg/ml in HBSS buffer) was added to each well, and luminescence intensity 
was measured using a multi-mode plate-reader (Victor X4, Perkin Elmer).
Data were plotted and analysed using the GraphPad Prism software and normalized as 
indicated in the relevant figure legends. The bias factors of formoterol for β44–V2R and 
β83–V2R were calculated with isoprenaline as a reference ligand following the equiactive 
comparison approach and equations described previously5.
Visualization of agonist-induced βarr1 trafficking
The βarr1–mYFP plasmid constructs used for confocal microscopy have been described 
previously45. HEK-293 cells were transfected with β1AR–V2R and βarr1–YFP plasmids. 
Twenty-four hours after transfection, 1 × 106 cells were seeded in 35-mm glass bottom 
confocal imaging plates pre-coated with 0.01% (w/v) poly-D-lysine. Cells were allowed to 
adhere for 24 h, and then serum-starved for 3–4 h. Cells were stimulated with 100 µM 
formoterol and live-cell imaging was carried out using a LSM780NLO confocal microscope 
fitted with 32x array GaAsP descanned detector (Zeiss) under 63×/1.40 NA objective with 
oil-immersion. A multiline argon laser source was used for monitoring YFP fluorescence 
and the raw images were processed with the ZEN lite (ZEN-black) software suite from 
Zeiss. For comparing the two β1AR–V2R constructs, imaging conditions including the laser 
intensity and pinhole settings were maintained in the same range.
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Expression and purification of nanobody Nb80
A synthetic gene (Integrated DNA Technologies) for Nb80 (ref. 6) was cloned into plasmid 
pET-26b(+) (Novagen) with an N-terminal His6 tag followed by a thrombin protease 
cleavage site. Expression in E. coli strain BL21(DE3)RIL (Agilent Technologies) and 
purification from the periplasmic fraction was as described elsewhere35. The His6 tag was 
removed by a thrombin (Sigma) protease cleavage step before concentration of the nanobody 
to 40 mg/ml.
Formation of formoterol-bound trx-β1AR-nanobody complex and purification with 
detergent exchange by size exclusion chromatography
Preparation of the receptor–nanobody complex was performed as described previously17. 
Formoterol-bound trx-β1AR (1.5 mg) was mixed with 1.5-fold molar excess of nanobody 
(0.65 mg), cholesteryl hemisuccinate (Sigma) was added to 0.1 mg/ml in a final volume of 
150 µl, and then the mixture was incubated for 2 h at room temperature.
After incubation, size-exclusion chromatography (SEC) was performed to separate the 
receptor–nanobody complex from excess nanobody and to exchange the detergent from DM 
to HEGA-10 (Anatrace) for crystallization by vapour diffusion. A Superdex 200 10/300 GL 
Increase column (GE Healthcare) was used at 4 °C. The column was equilibrated with SEC 
buffer (10 mM Tris-Cl− pH 7.4, 100 mM NaCl, 0.1 mM EDTA, 0.35% HEGA-10) 
supplemented with 10 µM formoterol. Samples containing complex were mixed with 200 µl 
SEC buffer and centrifuged (14,000g, 5 min) immediately before SEC (flow rate 0.2 ml/
min), with a run time of one hour which was sufficient for a near-complete detergent 
exchange as indicated by quantification of residual glycosidic detergent46. Peak fractions 
corresponding to complex were concentrated to 15 mg/ml for crystallization by vapour 
diffusion using 50 kDa-MWCO Amicon Ultra-4 centrifugal filter units (EMD-Millipore).
Crystallization of receptor–nanobody complex, data collection, processing and refinement
Crystals were grown in 150 + 150 nl sitting drops by vapour diffusion at 18 °C against 
reservoir solutions containing 0.1 M HEPES-Na+ pH 7.5 and 21–24% (w/v) PEG1500. 
Crystals usually appeared within 2 h and grew to full size (up to 200 µm in length) within 48 
h. Crystallization plates were equilibrated to 4 °C for at least 24 h before cryo-cooling. 
Crystals were picked with LithoLoops (Molecular Dimensions) and dipped in 0.1 M 
HEPES-Na+ pH 7.5, 25% (w/v) PEG1500, 5% (v/v) glycerol before plunging into liquid 
nitrogen.
Diffraction data for the trx-β1AR–Nb80 complex with formoterol bound were collected at 
ESRF, Grenoble using the autonomous beamline MASSIF-147. X-ray diffraction data were 
collected from a single point on the crystal using automatic protocols for the location and 
optimal centring of crystals48. The beam diameter was selected automatically to match the 
crystal volume of highest homogeneous quality and was therefore collimated to 30 µm, and 
strategy calculations accounted for flux and crystal volume in the parameter prediction for 
complete datasets49. Diffraction data were processed using MOSFLM50 and AIMLESS51, 
the structure was solved using PHASER52 with use of the crystal structures of the active 
state β2AR stabilized with nanobody Nb80 (ref. 6) and wild-type thioredoxin (PDB ID: 
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3P0G, 2H6X) as search models. Diffraction was anisotropic, as indicated by the estimated 
resolution limits (cross-correlation between intensities from half datasets (CC1/2) = 0.3) in 
h,k,l directions (Extended Data Table 2). To retain statistically significant diffraction data, 
but eliminating reflections in less well diffracting directions, the data were truncated 
anisotropically using the UCLA Diffraction Anisotropy Server (http://services.mbi.ucla.edu/
anisoscale/). Model refinement and rebuilding were carried out with REFMAC553 and 
Coot54.
Cloning, expression and purification of human βarr1
Wild-type human βarr1 was cloned into the pTrcHisB vector with a TEV protease-cleavable 
N-terminal His6 and Flag tag. Two mutations were introduced by site-directed mutagenesis: 
L68C, a finger-loop mutation commonly used in the functional labelling of arrestins31, and 
R169E, which disrupts the polar core and predisposes arrestin to activation55. Arrestin was 
expressed in BL21 cells. Cells were grown in LB medium supplemented with 100 µg/ml 
ampicillin at 25 °C. Expression was induced with 30 µM IPTG at a cell optical density at 
600 nm (OD600) of 0.5. The temperature was lowered to 15 °C and the cells allowed to grow 
for an additional 20 h. Cells were collected and flash-frozen in liquid nitrogen and stored at 
–80 °C. Arrestin was purified sequentially by Ni2+-affinity chromatography, TEV protease-
cleavage of its N-terminal affinity tags, and heparin chromatography, eluting off the heparin 
column using 1 M NaCl. Purified arrestin was further polished on a Superdex 200 prep 
grade column (GE Healthcare) equilibrated in 20 mM Tris-Cl− pH 8.0, 0.1 M NaCl, 10% 
(v/v) glycerol, 0.5 mM DTT. Peak fractions were pooled and concentrated to 20 mg/ml and 
flash-frozen as aliquots in liquid nitrogen and stored at –80 °C.
Expression and purification of zebrafish apo-lipoprotein A-1
Zebrafish apo-lipoprotein A-1 (zap1) was expressed and purified as previously described56. 
In brief, a pET-28a vector containing zap1 with a HRV-3C protease-cleavable N-terminal 
His6 tag was transformed into E. coli BL21(DE3)RIL cells. Cells were grown at 37 °C in TB 
medium supplemented with kanamycin. Expression was induced at OD600 1–1.5 with 1 mM 
IPTG. The temperature was lowered to 25 °C and the culture was allowed to grow for 3 h. 
Cells were lysed by sonication in the presence of 1% (v/v) Triton X-100. Cell lysate was 
clarified by centrifugation and passage through a 0.22-µm filter before loading onto a 
HisTrap-FF column. The pellet from the previous centrifugation step was resuspended in 
buffer containing 6 M guanidine hydrochloride (GnHCl), clarified by centrifugation, and 
loaded onto the HisTrap-FF column. The column was washed in successive buffers (base: 20 
mM Tris-Cl− pH 7.5, 0.3 M NaCl, 20 mM imidazole) containing first, 6 M GnHCl, then 
0.2% (v/v) Triton X-100, followed by 50 mM Na-cholate, before eluting in 20 mM Tris-Cl− 
pH 7.5, 150 mM NaCl, 20 mM Na-cholate, 0.3 M imidazole. Purified zap1 was treated with 
HRV-3C protease in the presence of 0.5 mM TCEP to remove the His6 tag before polishing 
on a Superdex 200 Increase column equilibrated in 20 mM Tris-Cl− pH 7.5, 150 mM NaCl, 
20 mM Na-cholate.
Expression and purification of Fab30
The coding region of Fab30 was synthesized by GenScript on the basis of the previously 
published crystal structure (PDB ID: 4JQI). For large-scale purification, Fab30 was 
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expressed in the periplasmic fraction of E. coli 55244 cells (ATCC) and purified using 
Protein L (GE Healthcare) gravity flow affinity chromatography as published previously31. 
In brief, cells containing Fab30 plasmid were used to inoculate 2xYT and grown overnight at 
30 °C. Fresh 2xYT was inoculated with 5% vol. initial inoculum and grown for an additional 
8 h at 30 °C. Cells were collected and resuspended in an equal volume of CRAP medium 
supplemented with ampicillin, and grown for 16 h at 30 °C.
For Fab30 purification, cells were lysed in Fab-lysis buffer (50 mM HEPES-Na+ pH 8.0, 0.5 
M NaCl, 0.5% (v/v) Triton X-100, 0.5 mM MgCl2) by sonication. Crude cell lysate was 
heated in a 65-°C water bath for 30 min and chilled immediately on ice for 5 min. 
Subsequently, lysate was clarified by centrifugation at 20,000g and passed through pre-
equilibrated Protein L resin packed gravity flow affinity column. After binding at room 
temperature, beads were washed extensively with wash buffer (50 mM HEPES-Na+ pH 8.0, 
0.5 M NaCl). Protein was eluted with 100 mM acetic acid into tubes containing 10% vol 
neutralization buffer (1 M HEPES pH 8.0). After elution, the sample was desalted into Fab-
storage buffer (20 mM HEPES-Na+ pH 8.0, 0.1 M NaCl) using a pre-packed PD-10 column 
(GE Healthcare). Purified Fab30 was flash-frozen and stored in buffer supplemented with 
10% (v/v) glycerol.
Functional validation of purified Fab30
The functionality of purified Fab30 was assessed using co-immunoprecipitation with 
reactivity towards V2Rpp-bound βarr1 as readout following a previously published 
protocol45. In brief, Fab30 (1.5 µg) was incubated with purified βarr1 (2.5 µg) in the 
presence or in the absence of V2Rpp (pre-incubated with 5–10 fold molar excess compared 
to βarr1) in 100–200 µl reaction volume. After 1 h incubation at room temperature, pre-
equilibrated Protein L beads were added to the reaction mixture and incubated for an 
additional 1 h. Subsequently, Protein L beads were washed 3–5 times using 20 mM HEPES-
Na+ pH 7.4, 150 mM NaCl, 0.01% (w/v) LMNG to remove non-specific binding. Bound 
proteins were eluted using 2 × SDS loading buffer and separated by SDS–PAGE. Interaction 
of Fab30 with activated βarr1 was visualized using Coomassie-staining and western blot.
Reconstitution of purified β1AR6P into nanodiscs and complex formation
Reconstitution was performed by adapting established protocols57. Stocks of 16:0-18:1 PC 
(POPC) and 16:0-18:1 PG (POPG, Avanti Polar Lipids) in chloroform were dried down 
under a nitrogen stream and fully solubilized in 20 mM HEPES-Na+ pH 7.5, 150 mM NaCl, 
100 mM Na-cholate to make 50 mM lipid stocks. β1AR6P (500 µg) was reconstituted into 
zap1-supported nanodiscs containing 7:3 (mol/mol) POPC:POPG. Receptor, zap1 and lipids 
at a molar ratio of 1:10:1,000 (net. 18 mM cholate) were mixed and incubated for an hour on 
ice. A threefold excess of damp, pre-equilibrated Bio-Beads SM-2 (Bio-Rad) was added in 
batch and the sample was mixed end-over-end overnight at 4 °C. An absorption capacity of 
80 mg cholate per gram was used to calculate the requisite amount of polystyrene beads58. 
The reconstituted sample, composed of a mixture of β1AR6P-incorporated nanodiscs and 
zap1/lipid-only nanodiscs, was further polished on a Superdex 200 Increase column 
equilibrated in 20 mM HEPES-Na+ pH 7.5, 150 mM NaCl, 5 µM formoterol.
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The nanodisc mixture was supplemented with a further 10 µM formoterol and incubated 
with a twofold excess of βarr1(L68C, R169E) for 1 h on ice. A twofold excess of His-tagged 
Fab30 was added and the mixture incubated for 1 h. Subsequently, the mixture was left to 
incubate in batch with 1 ml Ni-NTA resin (QIAGEN) overnight at 4 °C. A pull-down of 
β1AR6P–βarr1–Fab30 complex in nanodiscs was performed by Ni2+-chromatography 
exploiting His-tagged Fab30 to remove tag-free components—zap1/lipid-only nanodiscs and 
excess βarr1. The nanodisc-embedded ternary complex was separated from excess Fab30 on 
a Superdex 200 Increase column equilibrated in 10 mM HEPES-Na+ pH 7.5, 20 mM NaCl, 
2 µM formoterol. SEC fractions were either used immediately for cryo-EM grid preparation 
or divided into aliquots and flash frozen and stored at −80 °C. Grids prepared with freshly 
isolated complex or samples that had been subjected to a freeze/thaw cycle were identical in 
apparent quality.
β1AR6P–β-arrestin1–Fab30 cryo-grid preparation and data collection
Cryo-EM grids were prepared by applying 3 µl sample (at a protein concentration of 1 
mg/ml) on glow-discharged holey gold grids (Quantifoil Au 1.2/1.3 300 mesh). Excess 
sample was removed by blotting with filter paper for 2–3 s before plunge-freezing in liquid 
ethane (cooled to −181 °C) using a FEI Vitrobot Mark IV maintained at 100% relative 
humidity and 4 °C. Data collection was carried out on grids made from a single preparation 
of β1AR6P–βarr1–Fab30 complex. Images were collected on a FEI Titan Krios microscope at 
300 kV using a GIF Quantum K2 (Gatan) in counting mode. Data were collected in 3 
independent sessions—two on LMB-Krios2; one on Diamond eBIC-Krios1—to give a total 
of 18,581 movies. When processing previous datasets, particles were assessed by the 
software cryoEF59 to have an orientation distribution efficiency, Eod, of approximately 0.55, 
indicating moderately severe preferential orientation of the particles in freestanding ice. To 
improve orientation distribution, micrographs in this study were collected with a 30°-stage 
tilt. On LMB-Krios2, automated data acquisition was performed using serialEM60. Grid 
squares were subdivided into 3 × 3 grid hole-matrices. Stage shift was used to align the 
central grid hole within the acquisition template. Subsequently, image shift with active 
beam-tilt compensation was used to record from the nine holes. Large changes in sample 
height due to stage-tilt were compensated for by an equivalent degree of defocus adjustment, 
pre-determined and applied so as to normalize to the target defocus value. On eBIC-Krios1, 
data collection was performed using EPU (Thermo Fisher Scientific). Stage shift was used to 
centre individual grid holes. In all sessions, two non-overlapping exposures, aligned along 
the tilt axis, were collected per grid hole. Micrographs were collected with a fluence of 
around 45–50 e –/Å2. Each micrograph was collected as movie frames (around 1.0 e –/Å2/
frame) at a flux of 4.5 e –/pixel/s (LMB) or 3.3 e –/pixel/s (eBIC) with an energy selection 
slit width of 20 eV. The datasets were collected at a magnification of 105,000× (1.1 Å/pixel, 
LMB) and 130,000× (1.047 Å/pixel, eBIC).
Data processing and model building
RELION-3.0.7 was used for all data processing unless otherwise specified61. Drift, beam-
induced motion and dose-weighting were corrected in Warp-1.0.6 using a spatial resolution 
of 5 × 5 and a temporal resolution equal to the number of movie frames62. Contrast transfer 
function (CTF) estimation and determination of the focus gradient was performed in Warp 
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using movie frame input, with 5 × 5 spatial resolution and a temporal resolution of 1. 
Micrographs were curated for quality on the basis of ice contamination, CTF fitting quality, 
estimated resolution and astigmatism, resulting in a trimmed dataset of 18,101 micrographs. 
Auto-picking was performed with a Gaussian blob as a template, which resulted in optimal 
particle picking. The CTF parameters for the picked coordinates were interpolated from the 
focus gradients modelled in Warp. Particles were extracted in a box-size equivalent to 264 Å 
and downscaled initially to 4.4 Å/pixel. For each LMB-Krios2 session, micrographs were 
further separated into two halves, generating a total of five groups of particle stacks. Each 
group was processed independently. For each group, particles were subjected to two rounds 
of 3D classification in 6 classes using an ab initio model as reference. In the second round of 
3D classification, particle distribution appeared to be dictated in part by the size of the 
nanodisc component (Extended Data Fig. 4). Aberrant classes of particles, such as C4 and 
C5 (Extended Data Fig. 4) were excluded from subsequent rounds of processing, as they 
probably arose from distorted nanodiscs (C4) or aggregation effects (C5) that arose during 
grid preparation. Particles of varying nanodisc sizes were combined, re-extracted with 
downscaling to 1.69 Å/pixel, and refined to achieve an overall consensus alignment. Clear 
density could be observed for the transmembrane helices as well as two protrusions from the 
lipid boundary corresponding to ECL2 and ICL3, demarcating the volumes corresponding to 
receptor and zap1/lipid. Particles were subjected to Bayesian polishing before further 
refinement. Correcting for per-particle beam-induced motion consistently improved 
resolution by two resolution shells (according to a gold-standard Fourier shell correlation 
(FSC) of 0.143) at this early stage. Signal subtraction was performed to remove most of the 
non-receptor component of the nanodisc, facilitating refinement of the β1AR6P–βarr1–Fab30 
complex that included a thin annular layer of lipid. Subsequently, 3D classification without 
alignment into 6 classes (regularization parameter, T = 20) identified a subset of particles 
(around 8%) that refined to high resolution and showed fine map details in the receptor and 
arrestin regions. On trace-back, this subset of good particles constituted roughly an equal 
proportion of the class averages identified in the preceding round of 3D classification (that 
is, class distributions based loosely on nanodisc morphology). At this stage, the good 
particles from the five groups were combined, re-extracted with downscaling of 1.1 Å/pixel, 
and processed as a single dataset. The merged particle set was split according to microscope 
session for independent Bayesian polishing before re-merging for downstream processing. 
Following signal subtraction of the nanodisc and refinement, the model reached a resolution 
of 3.43 Å. Subsequently, refined particles were imported into and processed in RELION-3.1. 
On account of the image shift collection strategy used in LMB-Krios2, the particles from 
those two sessions were assigned to 1 of 18 optical groups—by sessions and based on 
position within their respective 3 × 3 matrices. Including the eBIC-Krios1 particles, this 
produced 19 optical group assignments, which were corrected independently for residual 
beam-tilt, anisotropic magnification, per-micrograph astigmatism, and per-particle CTF 
estimation. In the final refinement sequence, half maps were locally filtered between 
refinement iterations using SIDESPLITTER63, an adaptation of the LAFTER algorithm64 
that maintains gold-standard separation between the two half maps. The final model 
contained 403,991 particles and reached an overall resolution of 3.3 Å with side chains 
visible for most of the complex (Extended Data Figs. 3, 5). Local resolution estimates were 
calculated with RELION-3.1 showing the β1AR–βarr1 and βarr1–Fab30 interfaces at around 
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3.2 Å and rising gradually to around 3.7 Å at the level of the β1AR orthosteric binding site; 
H1 and the extracellular regions of the receptor, the C-distal end of arrestin, and CL–CH1 
domains of Fab30 are at poorer resolution, with the worst regions reaching about 4.5 Å at the 
most exposed edges. The final particle set was assessed to have Efvod ≈ 0.72.
Model building and refinement was carried out using the CCP-EM65 and PHENIX66 
software suites. The formoterol-bound trx-β1AR–Nb80 and βarr1–Fab30–V2Rpp crystal 
structures were used as starting models (PDB ID: 6IBL and 4JQI, respectively). β1AR was 
modelled from A42 to A358 with a gap from R243 to R279 (inclusive) on account of weak 
density. The V2R6P portion of β1AR6P was modelled from E372 to D384 (V2R numbering). 
The intervening linker region to A358 was too flexible to be resolved. Density for all 
phosphoresidues was well resolved. βarr1 was modelled from T6 to E359, with a gap 
between R331 and S340 (inclusive), which constitutes a region encompassing the C-distal 
'344-loop' that potentially interacts with the lipid head group region. Initial manual model 
building was performed in Coot54 following jelly-body refinement in Refmac553. Restraints 
for formoterol were generated using AM1 optimization in eLBOW67. To better maintain 
geometry in the regions of weak density, secondary structure restraints, Ramachandran 
restraints and rotamer restraints were applied during real space refinement in Phenix. The 
model followed iterative cycles of manual modification in Coot and restrained refinement in 
Phenix. The final model achieved good geometry (Extended Data Table 1) with validation of 
the model performed in Phenix, MolProbity68 and EMRinger69. The goodness of fit of the 
model to the map was carried out using Phenix using a global model-versus-map FSC 
(Extended Data Fig. 5). Over-fitting in refinement was monitored70 using FSCwork/FSCtest 
by refining a 'shaken' model against half map-1 and calculating a FSC of the resulting 
refined model against half map-2.
Expression and purification of mini-Gs 
Mini-Gs (construct R393) was expressed in E. coli strain BL21(DE3)RIL and purified by 
Ni2+-affinity chromatography, removal of the His tag using TEV protease and negative 
purification on Ni2+-NTA for protease and undigested mini-Gs removal, and final SEC to 
remove aggregated protein71. Purified mini-Gs was concentrated to a final concentration of 
100 mg/ml in 10 mM HEPES-Na+ pH 7.5, 100 mM NaCl, 10% (v/v) glycerol, 1 mM 
MgCl2, 1 µM GDP and 0.1 mM TCEP.
Radioligand binding studies on β1AR in nanodiscs
Purified MBP-β83 was ligated to V2R6P peptide to produce MBP–β1AR6P and inserted into 
nanodiscs in the absence of ligand. Nanodiscs containing MBP-β1AR6P were diluted into 
assay buffer for radioligand saturation binding studies as previously described for insect cell 
membranes17.
Competition binding assays
Nanodiscs containing MBP–β1AR6P were diluted in 20 mM HEPES-Na+ pH 7.5, 50 mM 
NaCl, 2.5 mM MgCl2, 0.1% BSA. Aliquots were supplemented with mini-Gs construct 
R393 or βarr1 (final concentration 25 µM), either formoterol or isoprenaline (8 points, with 
the final concentration between 1 pM and 100 µM), and apyrase (final concentration 0.1 
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U/ml; only with mini-Gs) to give a final volume of 120 µl. Samples were incubated at 20 °C 
for 1 h, before adding tritiated dihydroalprenolol ([3H]DHA) (Perkin Elmer) with 
concentrations of competing ligand in the range 1–2.5 × K d, where K d is the dissociation 
constant. Non-specific binding was determined by measuring binding in the presence of 100 
µM unlabelled ligand. Samples were incubated at 20 °C for 2 h, before filtering through 96-
well Multiscreen HTS GF/B filter plates (Merck Millipore) pre-soaked in 0.1% (w/v) 
polyethyleneimine, separating bound from unbound [3H]DHA. Filters were washed three 
times with 200 µl chilled assay buffer, dried, and then punched into scintillation vials with 4 
ml Ultima Gold scintillant (Perkin Elmer). Radioligand binding was quantified by 
scintillation counting with a Tri-Carb Liquid Scintillation Analyser (Perkin Elmer) and 
inhibitory constant (K i) values were determined using GraphPad Prism version 7.
Extended Data
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Extended Data Fig. 1. β1AR constructs, purification and activity.
a, Schematic of the constructs used for X-ray crystallography (trx-β1AR), cryo-EM (β83), 
radioligand binding (MBP-β83) and cell-based assays (β44–V2R, β83–V2R), indicating the 
sites of truncations, point mutations and tags. b, Purification scheme for the preparation of 
the β1AR6P–βarr1–Fab30 complex for structure determination by cryo-EM. c, d, 
Representative competition binding curves using either formoterol (c) or isoprenaline (d) 
show the high-affinity state of MBP–β1AR6P stabilized by either mini-Gs or βarr1. 
Experiments (Methods) to determine the high-affinity state were performed in a molar 
Lee et al. Page 17













excess of mini-Gs (green curves; n = 2) or βarr1 (red curves; n = 3 with formoterol, n = 4 
with isoprenaline) and compared to the low-affinity state (blue curves; n = 4). Experiments 
were all performed in duplicate, with the number of independent experiments indicated (n). 
Data are mean ± s.e.m. The apparent K i values were determined using the Cheng–Prusoff 
equation, using apparent K d values for [3H]DHA of 6 nM (MBP–β1AR6P and MBP–
β1AR6P + βarr1) and 1.5 nM (MBP–β1AR6P + mini-Gs). K i values for formoterol are 1.5 ± 
0.4 µM (MBP–β1AR6P), 42 ± 18 nM (MBP–β1AR6P + βarr1) and 0.7 ± 0.1 nM (MBP–
β1AR6P + mini-Gs). K i values for isoprenaline are 340 ± 70 nM (MBP–β1AR6P), 4.4 ± 0.8 
nM (MBP–β1AR6P + βarr1) and 0.13 ± 0.02 nM (MBP–β1AR6P + mini-Gs).
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Extended Data Fig. 2. Functional characterization of β1AR construct β83 in cells.
a, HEK293 cells expressing the two β1AR constructs β44–V2R (blue circles) and β83–V2R 
(red squares) together with the cAMP sensor 22F (GloSensor assay) were stimulated with 
the indicated concentrations of isoprenaline (dashed line) or formoterol (solid line). 
Subsequently, the luminescence readings were recorded and normalized with respect to the 
signal at the maximal dose of isoprenaline for β44–V2R (treated as 100%). The results are 
from four independent experiments of duplicate measurements, data are mean ± s.e.m. The 
maximum effect (E max) and half-maximal effective concentration (EC50) were calculated by 
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nonlinear regression (GraphPad Prism), data are mean ± s.e.m. b, HTLA cells expressing the 
β44–V2R (blue circles) and β83–V2R (red squares) Tango assay constructs (Methods) were 
stimulated with indicated concentrations of isoprenaline and formoterol, and the 
luminescence readings were recorded 8 h post-stimulation. Afterwards, the data were 
normalized with respect to the signal at the maximal dose of isoprenaline for β44–V2R 
(treated as 100%). Results are from five independent experiments of a duplicate 
measurement, data are mean ± s.e.m. E max and EC50 values were calculated by nonlinear 
regression (GraphPad Prism), data are mean ± s.e.m. c, Surface expression of β44–V2R and 
β83–V2R constructs in cells used for assays in a, b were measured by whole-cell ELISA 
using anti-Flag M2 antibody. Data are normalized with respect to β44–V2R (blue bars; 
treated as 100%). Values for p83–V2R are as follows: ELISA for G-protein assay, 99% ± 
13% (n = 5); ELISA for arrestin assay, 94% ± 17% (n = 4). Experiments were performed in 
duplicate with the number of independent experiments indicated (n), data are mean ± s.e.m. 
d, HEK293 cells expressing β44–V2R and β83–V2R together with βarr1–mYFP were 
stimulated with 100 µM formoterol for the indicated times and the localization of βarr1–
mYFP was monitored using live-cell confocal microscopy. Representative images from three 
independent experiments are shown. Scale bars, 10 µm.
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Extended Data Fig. 3. Cryo-EM single-particle reconstruction of the β1AR–βarr1‒Fab30 
complex.
a, Representative micrograph (LMB-Krios2, magnification 105,000×, defocus –1.9 µm) of 
the β1AR6P–βarr1–Fab30 complex collected using a Titan Krios with the GIF Quantum K2 
detector. b, Representative 2D class averages of the β1AR6P–βarr1–Fab30 complex 
determined using approximately 1 million particles after 3D classification. Copies of the 
final reconstruction are juxtaposed to indicate relative orientations. c, FSC curve of the final 
reconstruction (black) showing an overall resolution of 3.3 Å using the gold standard FSC of 
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0.143. The directional 3D-FSC curves calculated from the two half maps are shown in 
colour72. d, Final reconstruction coloured by polypeptides (contour level 0.023). e. Local 
resolution estimation of the β1AR6P–βarr1–Fab30 map as calculated by Relion.
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Extended Data Fig. 4. Flow chart of cryo-EM data processing.
Micrographs were collected during three sessions on a Titan Krios (between 48-h and 96-h 
long) using a 30° stage tilt to improve particle orientation distribution. Each dataset was 
corrected separately for drift, beam-induced motion and radiation damage. After focus 
gradient and CTF estimation, particles were picked using a Gaussian blob. At this stage, 
each of the LMB Krios2 datasets was split into two halves by micrographs, generating a 
total of five groups of particles. Each group was processed and curated independently. The 
number of particles from group G1 is indicated on the flowchart as a guide. At the bottom of 
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the figure, the final number of particles is shown. Particles were submitted to two rounds of 
3D classification using an ab initio model as a reference. In each round, classification was 
performed in six classes. The models with the best features were merged and refined 
together before correcting for per-particle beam-induced motion. Subtracted particles were 
generated by removing most of the non-receptor nanodisc signal and refined. 3D 
classification without alignment was performed in six classes using a mask encompassing 
the entire complex. The models showing the best features were refined either individually or 
in combination. The quality of the models was judged on the basis of both resolution and 
map features and weighed against the size of the contributing particle set (the resolution of 
the models refers to the resolution after refinement and calculation of gold-standard FSC of 
0.143). The best particles from each group were merged and re-extracted. After merging, the 
combined particle set was processed together except at the stage of per-particle beam-
induced motion correction, at which particles were split into their session-stacks for 
Bayesian polishing. Particles were assigned to one of 19 optical groups (Methods) and 
corrected iteratively for beam-tilt, per-micrograph astigmatism, anisotropic magnification 
and per-particle CTF estimation. A final model with 403,991 particles was refined and 
achieved a global resolution of 3.3 Å.
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Extended Data Fig. 5. Cryo-EM map quality of the β1AR6P–βarr1–Fab30 complex and model 
validation.
Unless otherwise stated, density maps were visualized using Chimera38 (contour level 
0.017) and encompass a radius of 2 Å around the region of interest. a, Transmembrane 
helices of β1AR6P with density shown as a mesh. b, ICL2 of β1AR6P. For clarity, the 
neighbouring βarr1 side chains are depicted without density. c, ECL3 of β1AR6P and the 
adjacent helical turns of H6 and H7. d, The phosphorylated V2R6P C terminus. Inset, 
interaction between the V2R6P phospho-threonine dyad and the βarr1 lariat loop. Density in 
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the inset is depicted with contour level 0.01 (carve radius 2 Å). e, The finger loop of βarr1. f, 
Formoterol and the neighbouring side chains in the orthosteric binding site. g, FSC of the 
refined model versus the map (green curve), and FSCwork and FSCfree validation curves 
(blue and red curves, respectively). h, Amino acid sequence of the β1AR6P construct used 
for the cryo-EM structure determination. The residues are numbered according to the wild-
type sequence of β1AR. Residues are coloured according to how they have been modelled 
(key). Regions highlighted in grey represent the transmembrane α-helices, amphipathic 
helix 8 is highlighted in yellow, and phosphorylated residues are highlighted in green. The 
dashes represent amino acid residues that were deleted.
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Extended Data Fig. 6. Comparison of arrestin coupled to different GPCRs.
a, Superposition of arrestin molecules in the complexes of β1AR6P–βarr1 (green) and 
rhodopsin–arrestin (pale brown). The different angle between the respective receptors and 
coupled arrestins is shown by the 20° difference in tilt of H3 (blue, H3 in rhodopsin; red, H3 
in β1AR). b, Superposition of β1AR6P and β2AR (pink and purple cartoons, respectively) 
coupled to either βarr1 (magenta surface) or Gs (blue and purple surfaces), respectively. c, 
Superposition of β1AR6P (rainbow cartoon) and NTSR1 (grey cartoon) coupled to βarr1 
(magenta) and βarr1 (grey), respectively. d, Alignment in c viewed from the membrane 
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surface and the respective molecules of βarr shown in surface representation. e, 
Superposition of the active state of βarr1 (pale brown; PDB ID: 4JQI) not bound to receptor 
and βarr1 (green) coupled to β1AR6P. The phosphopeptides are shown as sticks: yellow 
carbon atoms, V2Rpp in 4JQI; magenta carbon atoms, V2R6P in the β1AR6P–βarr1 complex.
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Extended Data Fig. 7. β1AR6P–βarr1 and formoterol–β1AR6P contacts, and comparison with 
other complexes.
a, interactions between amino acid residues in β1AR6P and βarr1. The size of the circle 
depicting the residue is proportional to the number of van der Waals interactions (grey lines) 
and hydrogen bonds (red lines) made, with residues in circles outlined in black making 
potential hydrogen bonds. Secondary structure elements are shown with the total number of 
interactions they make. The thickness of lines making contacts is proportional to the number 
of contacts made. b, Residues are depicted in β1AR6P that make contact (≤3.9 Å) with βarr1 
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(red) and residues in β2AR (PDB ID: 3SN6) that make contact to Gs (blue); purple residues 
make contacts in both structures. The sequence of turkey β1AR is depicted. c, Residues in 
human rhodopsin that make contact with either visual arrestin or transducin (Gt). Plots were 
made using GPCRdb. d, The number of atomic contacts between the ligand formoterol and 
secondary structure elements in β1AR is depicted; grey bars, β1AR–Nb80 complex; blue 
bars, β1AR6P–βarr1 complex. Light regions correspond to the number of van der Waals 
interactions and dark regions correspond to the number of hydrogen bonds. Data for chain A 
and chain B in the crystal unit cell of the β1AR–Nb80 complex are shown separately (A and 
B).
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Extended Data Fig. 8. Comparison of the visual arrestin and βarr1 interfaces with GPCRs and 
lipids.
a, A snake plot (GPCRdb) of human βarr1 depicts the secondary structure elements in the 
protein, with amino acid residues that make contact with β1AR coloured blue. Equivalent 
regions in mouse visual arrestin (S-arr) that make contact to rhodopsin are shown in red. 
Alignments of human arrestins show the variation of amino acid sequences within these 
specific regions, with residues that make contact to the respective receptors highlighted. 
Highlighted are residues equivalent to those in visual arrestin that have been shown by 
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mutagenesis to interact with phosphoinositides by mutagenesis (&)31 or to interact with the 
lipid bilayer by bimane fluorescence quenching ($)28. b, c, β1AR6P is depicted in surface 
representation and βarr1 as a cartoon (green) with atoms predicted to be within the head 
group region of the lipid bilayer shown as spheres: oxygen, red; nitrogen, blue; carbon, 
green or cyan. Residues coloured cyan are predicted to be entirely within the lipid head 
group region, while the carbons coloured green are the portions of these side chains that are 
potentially interacting with lipid head groups. b, c, View of the lipid-interacting surface 
viewed parallel to the membrane plane (b) and through the receptor (c).
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Extended Data Fig. 9. Conformational changes in β1AR and potential drug-interaction sites to 
discriminate between complexes of β-adrenoceptors coupled to either βarr1 or Gs.
a, The inactive state (R) of β1AR binds agonist (blue hexagon) resulting in an inward 
movement of H5 in the orthosteric binding pocket (yellow arrow), to form an intermediate 
state (R′). Coupling of G protein results in outward movement of the cytoplasmic ends of 
H5 and H6 (red arrow) and contraction of the orthosteric binding site (yellow arrows). 
Displacement of G protein by arrestin results in an inward movement of the cytoplasmic 
ends of H5 and H6 (red arrow) and an outward movement of H5 in the orthosteric biding 
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pocket (yellow arrow). Receptors in the R* state have higher affinity for agonists than those 
in the R state. Representative structures of each of the states depicted have been determined, 
but in reality there is likely to be a continuum of states between them. Several factors 
probably affect the arrestin bias of ligands, not just the structure of the receptor–arrestin 
complex. b, Surface view of β1AR6P showing the finger loop of βarr1 (sticks). c, Surface 
view of β2AR showing the α5 helix of Gs (sticks). In b, c, potential druggable sites are 
depicted (magenta oval) in b and c that could be used to develop small molecules that 
discriminate between the same receptor coupled to either βarr1 or Gs. d, e, Two examples of 
small-molecule negative allosteric modulators that bind to the surface of GPCRs, which give 
a proof of concept to the surface-interacting molecules.
Extended Data Table 1
Cryo-EM data collection and refinement statistics
Formoterol-bound β1AR–β-arrestin-1–Fab30
EMDB-10515; PDB 6TKO
Session LMB Krios2-1 LMB Krios2-2 DLS eBIC Krios 1
Data collection and processing
Magnification 105,000x 105,000x 130,000x
Voltage (kV) 300 300 300
Electron exposure (e–/Å2) 51 49 45
Defocus range (µm) -1.2 to-3.0 -1.2 to -3.0 -1.2 to-3.0
Pixel size (Å) 1.1 1.1 1.047
Symmetry imposed C1 C1 C1
Initial particle images* (no.) 2,257,195 1,959,236 448,633
Contribution to final particle images (no.) 175,204 183,140 45,647
Final particle images (no.) 403,991
Map resolution (Å) 3.3
    FSC threshold 0.143
Map resolution range† (Å) ~3.2 to ~4.5
Refinement
Initial model used (PDB code) 6IBL, 4JQI
Model resolution‡ (Å) 3.66
    FSC threshold 0.5
Map sharpening B factor (Å2) -80
Model composition
    Non-hydrogen atoms 8,085
    Protein residues 1,052
    Ligands 25
B factors (Å2)
    Protein 80.5
    Ligand 115
R.m.s. deviations
    Bond lengths (Å) 0.001
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    Bond angles (°) 0.411
Validation
    Molprobity score 1.06
    Clashscore 2.75
    Poor rotamers (%) 0.23
    EMRinger score 2.06
Ramachandran plot
    Favored (%) 99.02
    Allowed (%) 0.98






Resolution at which FSC between map and model is 0.5.
Extended Data Table 2




Number of crystals 1
Space group P 21 21 21
Cell dimensions a, b, c (Å) 116.6, 121.1, 129.8
Resolution range (Å) 44.28-2.7 (2.79-2.7)*
Unique reflections 50,611 (4,416)*
Completeness before truncation (%) 99.0 (95.3)*
Multiplicity 4.6 (4.7)*
Mean |/σ| 6.6 (1.7)*
Rmerge 0.151 (0.936)*
CC1/2=0.3 h, k, I axes & overall (Å) 2.7, 3.62, 3.43, 2.92
Refinement statistics
Resolution (Å) 88.6-2.7 (2.78-2.7)*
Completeness, truncated data (%) 62.71 (2.78)
No. of reflections 30,378
Rwork/Rfree (%) 0.242/0.276 (0.323/0.348)*
No. of atoms 8,271
    Protein 7,984
    Ligands & detergents 258
    Water 29
B-factors (Å2)
    Protein 70.2
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    Ligand & detergents 57.9, 73.8
    Waters 38.5
R.M.S.D.
    Bond lengths (Å) 0.008




Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Overall cryo-EM reconstruction of the β1AR6P–βarr1 complex.
a, Overall structure of the β1AR6P–βarr1–Fab30 complex containing bound formoterol 
(magenta). b, The density of the cryo-EM map (sharpened with a B factor of –80 Å2) is 
coloured according to polypeptides (β1AR6P, blue; βarr1, green) and overlaid on the density 
of the nanodisc (grey). Fab30 has been omitted from the structure for clarity (Extended Data 
Fig. 3). c, The orthosteric binding pocket of β1AR6P (pale blue) with formoterol (shown as 
sticks: carbon, yellow; oxygen, red; nitrogen, blue) and its density in the cryo-EM map (grey 
mesh). d, The finger loop of βarr1 with side chains shown as sticks (carbon, light green) and 
its density in the cryo-EM map (grey mesh). Helix 8 of β1AR6P has been removed for 
clarity. Maps were contoured at 0.02 (2 Å carve radius in b, c) and visualized in Chimera38. 
e, Crystal structure of the β1AR–Nb80 complex. β1AR, rainbow colouration; Nb80, grey; 
thioredoxin, brown; formoterol, magenta spheres (carbon); water molecules, red spheres. 
The inset shows an omit map of formoterol in the β1AR–Nb80 complex contoured at 1σ 
(blue mesh).
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Fig. 2. Structure of βarr1 in complex with β1AR6p.
a, βarr1 (pale green) coupled to β1AR6P (surface representation) was aligned with the 
structures of visual arrestin (pale brown) coupled to rhodopsin (PDB ID: 5W0P) and the 
structure of active βarr1 (mauve) bound to the phosphopeptide V2Rpp and Fab30 (PDB ID: 
4JQI). The phosphopeptide shown (carbon, magenta) is V2R6P in β1AR6P. Full alignments 
of the phosphopeptides are shown in Extended Data Fig. 6e. b–e, Details of coupled arrestin 
finger loops and G protein α5 helices after alignment of the following receptors (PDB code 
in parentheses) using GESAMT (CCP4 program suite): visual arrestin coupled to rhodopsin 
(5W0P, pale brown); transducin (Gt) coupled to rhodopsin (6OYA, pale pink); βarr1 coupled 
to β1AR6P (pale green); Nb80 coupled to β1AR (6IBL, grey); Gs coupled to β2AR (3SN6, 
blue).
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Fig. 3. Comparison of the receptor-coupling interfaces in the β1AR6P–βarr1 and β2AR–Gs 
complexes.
a, Snake plot of the intracellular region of turkey β1AR with amino acid residues colour-
coded according to interactions: red, contact between β1AR6P and βarr1; blue, contact 
between β2AR and Gs; purple, both contacts. b, c, Cross-sections through the intracellular 
halves of β2AR (b) and β1AR6P (c) to highlight the different shapes of the intracellular cleft 
formed upon coupling of βarr1 compared with Gs. Transmembrane helices are shown for 
orientation, and are in front of the cross-section. d, Detail of the interface between the βarr1 
finger loop (pale green) and β1AR6P (pale blue). e, Detail of the interface between the α5 
helix of the Gs α-subunit (blue) and β2AR (green). Depicted in d, e are polar interactions 
(red dashes), van der Waals interactions (blue dashes; atoms ≤ 3.9 Å apart) and Arg3.50 
(shown as sticks: carbon, grey).
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Fig. 4. Differences between formoterol-bound β1AR coupled to either βarr1 or Nb80.
a-c, Superposition of β1AR6P coupled to βarr1 (blue) and β1AR coupled to Nb80 (grey), 
with residues interacting with the ligand shown as sticks. Residues labelled in orange 
interact with formoterol but not isoprenaline. d, Structures of arrestin-biased ligands 
(formoterol, carvedilol) and a balanced agonist (isoprenaline). Regions in blue are identical 
to adrenaline, and the red region in carvedilol is the oxypropylene linker that is typical of β-
adrenoceptor antagonists of the G-protein pathway.
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